Class information for:
Level 1: PLATINUM RESISTANT//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2971 2022 29.8 70%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1449 7299 INTRAPERITONEAL CHEMOTHERAPY//CYTOREDUCTIVE SURGERY//PERITONEAL CARCINOMATOSIS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PLATINUM RESISTANT Author keyword 39 61% 2% 41
2 RECURRENT OVARIAN CANCER Author keyword 38 39% 4% 75
3 PEGYLATED LIPOSOMAL DOXORUBICIN Author keyword 33 33% 4% 84
4 RELAPSED OVARIAN CANCER Author keyword 27 78% 1% 18
5 TOPOTECAN Author keyword 25 17% 7% 137
6 PLATINUM SENSITIVE Author keyword 20 57% 1% 24
7 PLATINUM FREE INTERVAL Author keyword 11 67% 0% 10
8 ADVANCED OVARIAN CANCER Author keyword 9 23% 2% 35
9 PLATINUM RESISTANT OVARIAN CANCER Author keyword 9 67% 0% 8
10 RECURRENT OVARIAN CARCINOMA Author keyword 8 52% 1% 11

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 PLATINUM RESISTANT 39 61% 2% 41 Search PLATINUM+RESISTANT Search PLATINUM+RESISTANT
2 RECURRENT OVARIAN CANCER 38 39% 4% 75 Search RECURRENT+OVARIAN+CANCER Search RECURRENT+OVARIAN+CANCER
3 PEGYLATED LIPOSOMAL DOXORUBICIN 33 33% 4% 84 Search PEGYLATED+LIPOSOMAL+DOXORUBICIN Search PEGYLATED+LIPOSOMAL+DOXORUBICIN
4 RELAPSED OVARIAN CANCER 27 78% 1% 18 Search RELAPSED+OVARIAN+CANCER Search RELAPSED+OVARIAN+CANCER
5 TOPOTECAN 25 17% 7% 137 Search TOPOTECAN Search TOPOTECAN
6 PLATINUM SENSITIVE 20 57% 1% 24 Search PLATINUM+SENSITIVE Search PLATINUM+SENSITIVE
7 PLATINUM FREE INTERVAL 11 67% 0% 10 Search PLATINUM+FREE+INTERVAL Search PLATINUM+FREE+INTERVAL
8 ADVANCED OVARIAN CANCER 9 23% 2% 35 Search ADVANCED+OVARIAN+CANCER Search ADVANCED+OVARIAN+CANCER
9 PLATINUM RESISTANT OVARIAN CANCER 9 67% 0% 8 Search PLATINUM+RESISTANT+OVARIAN+CANCER Search PLATINUM+RESISTANT+OVARIAN+CANCER
10 RECURRENT OVARIAN CARCINOMA 8 52% 1% 11 Search RECURRENT+OVARIAN+CARCINOMA Search RECURRENT+OVARIAN+CARCINOMA

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PLATINUM RESISTANT 117 69% 5% 101
2 STAGE III 81 21% 17% 344
3 SINGLE AGENT PACLITAXEL 70 79% 2% 45
4 GYNECOLOGIC ONCOLOGY GROUP 53 11% 23% 462
5 REFRACTORY OVARIAN 43 60% 2% 47
6 RESISTANT OVARIAN 33 67% 1% 29
7 CYCLOPHOSPHAMIDE PLUS CISPLATIN 32 85% 1% 17
8 PLATINUM RESISTANT DISEASE 32 88% 1% 15
9 EPIDOXORUBICIN PLUS PACLITAXEL 30 100% 1% 12
10 PACLITAXEL RESISTANT OVARIAN 29 77% 1% 20

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Latest research and treatment of advanced-stage epithelial ovarian cancer 2013 65 93 29%
Management Strategies for Recurrent Platinum-Resistant Ovarian Cancer 2011 43 67 69%
Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy 2007 38 24 88%
Management of platinum-sensitive recurrent ovarian cancer 2006 45 15 93%
Role of pegylated liposomal doxorubicin in ovarian cancer 2005 65 32 66%
Pharmaceutical management of ovarian cancer - Current status 2008 58 195 48%
First-Line Therapy in Ovarian Cancer Trials 2011 29 18 72%
Maintenance chemotherapy in the management of epithelial ovarian cancer 2015 1 37 41%
Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions 2009 38 108 84%
Therapeutic strategies in epithelial ovarian cancer 2012 47 38 32%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 HEMATOL MED ONCOL R35 4 75% 0.1% 3
2 OVARIAN CANC ACT HHMT 4 75% 0.1% 3
3 CLEVELAND CLIN TAUSSIG CANC R35 3 100% 0.1% 3
4 KLIN GYNAKOL GYNAKOL ONKOL 2 22% 0.4% 9
5 BRAS FAMILY DRUG DEV PROGRAM 2 43% 0.1% 3
6 MED GYNECOL ONCOL UNIT 2 43% 0.1% 3
7 PROGRAM GYNECOL MED ONCOL 2 33% 0.2% 4
8 GILLETTE WOMENS STUDIES 1 100% 0.1% 2
9 GYNECOL CANC COOPERAT GRP 1 100% 0.1% 2
10 LAKESIDE VA MED 1 100% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000240926 INTERVAL DEBULKING SURGERY//SECONDARY CYTOREDUCTIVE SURGERY//ADVANCED OVARIAN CANCER
2 0.0000233592 INTRAPERITONEAL CHEMOTHERAPY//INTRAPERITONEAL//INTRAPERITONEAL THERAPY
3 0.0000193581 OREGOVOMAB//AFLIBERCEPT//GI PERFORATION
4 0.0000105132 HYPERSENSITIVITY REACTIONS//HYPERSENSITIVITY REACTION//CARBOPLATIN HYPERSENSITIVITY
5 0.0000102363 TRIMELAMOL//HEXAMETHYLMELAMINE//DEHYDROEMETINE
6 0.0000096670 CALVERT FORMULA//CHATELUT FORMULA//SKI 2053R
7 0.0000069687 METASTATIC BREAST CANCER//VINORELBINE//DOCETAXEL
8 0.0000060520 ARID1A//CLEAR CELL CARCINOMA//OVARIAN CLEAR CELL CARCINOMA
9 0.0000057621 NAB PACLITAXEL//CREMOPHOR EL//NEW MAT BIOL
10 0.0000056244 CAMPTOTHECIN//SN 38//TOPOTECAN